|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C4orf32 |
Gene summary for C4ORF32 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C4orf32 | Gene ID | 132720 |
| Gene name | family with sequence similarity 241 member A | |
| Gene Alias | C4orf32 | |
| Cytomap | 4q25 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N8J7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 132720 | C4orf32 | P2T-E | Human | Esophagus | ESCC | 1.47e-12 | 2.38e-01 | 0.1177 |
| 132720 | C4orf32 | P5T-E | Human | Esophagus | ESCC | 3.92e-02 | 6.02e-02 | 0.1327 |
| 132720 | C4orf32 | P9T-E | Human | Esophagus | ESCC | 4.61e-05 | 3.84e-03 | 0.1131 |
| 132720 | C4orf32 | P16T-E | Human | Esophagus | ESCC | 1.60e-05 | -7.43e-02 | 0.1153 |
| 132720 | C4orf32 | P20T-E | Human | Esophagus | ESCC | 1.78e-13 | 6.18e-02 | 0.1124 |
| 132720 | C4orf32 | P22T-E | Human | Esophagus | ESCC | 2.04e-08 | 2.02e-01 | 0.1236 |
| 132720 | C4orf32 | P23T-E | Human | Esophagus | ESCC | 2.67e-06 | 2.48e-01 | 0.108 |
| 132720 | C4orf32 | P24T-E | Human | Esophagus | ESCC | 9.02e-04 | 1.74e-01 | 0.1287 |
| 132720 | C4orf32 | P26T-E | Human | Esophagus | ESCC | 3.98e-17 | 1.93e-01 | 0.1276 |
| 132720 | C4orf32 | P27T-E | Human | Esophagus | ESCC | 7.78e-11 | -1.50e-02 | 0.1055 |
| 132720 | C4orf32 | P28T-E | Human | Esophagus | ESCC | 2.04e-05 | -3.45e-02 | 0.1149 |
| 132720 | C4orf32 | P30T-E | Human | Esophagus | ESCC | 1.99e-07 | 5.71e-02 | 0.137 |
| 132720 | C4orf32 | P32T-E | Human | Esophagus | ESCC | 1.22e-10 | 1.80e-01 | 0.1666 |
| 132720 | C4orf32 | P36T-E | Human | Esophagus | ESCC | 1.20e-08 | 1.25e-01 | 0.1187 |
| 132720 | C4orf32 | P37T-E | Human | Esophagus | ESCC | 7.57e-10 | -4.01e-02 | 0.1371 |
| 132720 | C4orf32 | P38T-E | Human | Esophagus | ESCC | 9.27e-15 | 5.61e-01 | 0.127 |
| 132720 | C4orf32 | P39T-E | Human | Esophagus | ESCC | 4.21e-10 | 2.77e-02 | 0.0894 |
| 132720 | C4orf32 | P40T-E | Human | Esophagus | ESCC | 3.41e-07 | 1.12e-01 | 0.109 |
| 132720 | C4orf32 | P42T-E | Human | Esophagus | ESCC | 9.47e-10 | 2.35e-01 | 0.1175 |
| 132720 | C4orf32 | P47T-E | Human | Esophagus | ESCC | 5.09e-04 | -8.03e-02 | 0.1067 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C4orf32 | SNV | Missense_Mutation | novel | c.206A>C | p.Lys69Thr | p.K69T | Q8N8J7 | protein_coding | deleterious(0.01) | probably_damaging(0.918) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C4orf32 | SNV | Missense_Mutation | rs200998231 | c.312C>A | p.Phe104Leu | p.F104L | Q8N8J7 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C4orf32 | SNV | Missense_Mutation | rs200998231 | c.312N>A | p.Phe104Leu | p.F104L | Q8N8J7 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C4orf32 | SNV | Missense_Mutation | rs200998231 | c.312N>A | p.Phe104Leu | p.F104L | Q8N8J7 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C4orf32 | SNV | Missense_Mutation | novel | c.292N>A | p.Glu98Lys | p.E98K | Q8N8J7 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C4orf32 | SNV | Missense_Mutation | rs200998231 | c.312N>A | p.Phe104Leu | p.F104L | Q8N8J7 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| C4orf32 | SNV | Missense_Mutation | c.338G>T | p.Gly113Val | p.G113V | Q8N8J7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| C4orf32 | SNV | Missense_Mutation | c.160G>C | p.Glu54Gln | p.E54Q | Q8N8J7 | protein_coding | tolerated(0.42) | benign(0.007) | TCGA-56-A5DR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C4orf32 | insertion | Frame_Shift_Ins | novel | c.333_334insTGTGAGTCTTCAACAT | p.Leu112CysfsTer39 | p.L112Cfs*39 | Q8N8J7 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |